黑色素-话题@MedSci

#黑色素#

1110篇内容 | 1890人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1559024, encodeId=51781559024bd, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=PD1+溶瘤病毒，奥源和力公布OrienX010一项黑色素瘤Ib期研究结果, objectType=article, longId=201030, objectId=51052010304a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=51052010304a, replyNumber=0, likeNumber=62, createdTime=2020-09-23, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=51052010304a, moduleTitle=PD1+溶瘤病毒，奥源和力公布OrienX010一项黑色素瘤Ib期研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=51052010304a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1565033, encodeId=e0da156503386, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=PD1+溶瘤病毒，奥源和力公布OrienX010一项黑色素瘤Ib期研究结果, objectType=article, longId=201030, objectId=51052010304a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=51052010304a, replyNumber=0, likeNumber=63, createdTime=2020-09-23, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=51052010304a, moduleTitle=PD1+溶瘤病毒，奥源和力公布OrienX010一项黑色素瘤Ib期研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=51052010304a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1565146, encodeId=3c6d1565146f5, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=Clin Cancer Res：抗疟疾药氯喹可增加GNAQ/11突变性黑色素瘤对MEK1/2抑制剂的敏感性！, objectType=article, longId=200796, objectId=d03f200e96fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d03f200e96fe, replyNumber=0, likeNumber=92, createdTime=2020-09-18, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d03f200e96fe, moduleTitle=Clin Cancer Res：抗疟疾药氯喹可增加GNAQ/11突变性黑色素瘤对MEK1/2抑制剂的敏感性！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d03f200e96fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1559137, encodeId=9076155913e0a, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=Clin Cancer Res：抗疟疾药氯喹可增加GNAQ/11突变性黑色素瘤对MEK1/2抑制剂的敏感性！, objectType=article, longId=200796, objectId=d03f200e96fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d03f200e96fe, replyNumber=0, likeNumber=107, createdTime=2020-09-18, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d03f200e96fe, moduleTitle=Clin Cancer Res：抗疟疾药氯喹可增加GNAQ/11突变性黑色素瘤对MEK1/2抑制剂的敏感性！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d03f200e96fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1559023, encodeId=ef32155902367, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=NEJM：Dabrafenib联合Trametinib 治疗III期黑色素瘤患者长期生存数据喜人, objectType=article, longId=200218, objectId=b6bb200218dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6bb200218dc, replyNumber=0, likeNumber=16, createdTime=2020-09-05, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6bb200218dc, moduleTitle=NEJM：Dabrafenib联合Trametinib 治疗III期黑色素瘤患者长期生存数据喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6bb200218dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1565032, encodeId=aac5156503256, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=NEJM：Dabrafenib联合Trametinib 治疗III期黑色素瘤患者长期生存数据喜人, objectType=article, longId=200218, objectId=b6bb200218dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6bb200218dc, replyNumber=0, likeNumber=14, createdTime=2020-09-05, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6bb200218dc, moduleTitle=NEJM：Dabrafenib联合Trametinib 治疗III期黑色素瘤患者长期生存数据喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6bb200218dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1565031, encodeId=4f941565031e1, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=Clin Cancer Res：靶向细胞外基质重构可恢复BRAFi耐药性黑色素瘤对BRAF抑制剂的敏感性, objectType=article, longId=200028, objectId=1381200028b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1381200028b8, replyNumber=0, likeNumber=55, createdTime=2020-08-30, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1381200028b8, moduleTitle=Clin Cancer Res：靶向细胞外基质重构可恢复BRAFi耐药性黑色素瘤对BRAF抑制剂的敏感性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1381200028b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1559022, encodeId=4aae1559022c9, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=Clin Cancer Res：靶向细胞外基质重构可恢复BRAFi耐药性黑色素瘤对BRAF抑制剂的敏感性, objectType=article, longId=200028, objectId=1381200028b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1381200028b8, replyNumber=0, likeNumber=67, createdTime=2020-08-30, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1381200028b8, moduleTitle=Clin Cancer Res：靶向细胞外基质重构可恢复BRAFi耐药性黑色素瘤对BRAF抑制剂的敏感性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1381200028b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1559021, encodeId=3aad15590212e, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=Ann Oncol：黑色素瘤新辅助治疗后pCR患者的组织病理学特征与无复发生存相关, objectType=article, longId=198987, objectId=cadf19898eaa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cadf19898eaa, replyNumber=0, likeNumber=78, createdTime=2020-08-09, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cadf19898eaa, moduleTitle=Ann Oncol：黑色素瘤新辅助治疗后pCR患者的组织病理学特征与无复发生存相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cadf19898eaa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1565030, encodeId=c25115650305c, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=Ann Oncol：黑色素瘤新辅助治疗后pCR患者的组织病理学特征与无复发生存相关, objectType=article, longId=198987, objectId=cadf19898eaa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cadf19898eaa, replyNumber=0, likeNumber=73, createdTime=2020-08-09, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cadf19898eaa, moduleTitle=Ann Oncol：黑色素瘤新辅助治疗后pCR患者的组织病理学特征与无复发生存相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cadf19898eaa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1565029, encodeId=30e0156502901, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=肺原发黑色素瘤一例, objectType=article, longId=198935, objectId=288a1989355d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=288a1989355d, replyNumber=0, likeNumber=37, createdTime=2020-08-09, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=288a1989355d, moduleTitle=肺原发黑色素瘤一例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=288a1989355d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1559020, encodeId=4d74155902018, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=肺原发黑色素瘤一例, objectType=article, longId=198935, objectId=288a1989355d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=288a1989355d, replyNumber=0, likeNumber=52, createdTime=2020-08-09, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=288a1989355d, moduleTitle=肺原发黑色素瘤一例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=288a1989355d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1559019, encodeId=674c15590196d, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=罗氏PD-L1单抗Tecentriq联合靶向疗法：获FDA批准治疗晚期黑色素瘤, objectType=article, longId=198563, objectId=ec5d198563ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec5d198563ab, replyNumber=0, likeNumber=12, createdTime=2020-08-03, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec5d198563ab, moduleTitle=罗氏PD-L1单抗Tecentriq联合靶向疗法：获FDA批准治疗晚期黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec5d198563ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1565028, encodeId=d99e1565028a2, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=罗氏PD-L1单抗Tecentriq联合靶向疗法：获FDA批准治疗晚期黑色素瘤, objectType=article, longId=198563, objectId=ec5d198563ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec5d198563ab, replyNumber=0, likeNumber=16, createdTime=2020-08-03, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec5d198563ab, moduleTitle=罗氏PD-L1单抗Tecentriq联合靶向疗法：获FDA批准治疗晚期黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec5d198563ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1559018, encodeId=2c89155901878, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=黑色素性神经鞘瘤2例报道, objectType=article, longId=198388, objectId=d206198388fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d206198388fd, replyNumber=0, likeNumber=53, createdTime=2020-08-01, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d206198388fd, moduleTitle=黑色素性神经鞘瘤2例报道, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d206198388fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1565027, encodeId=4acd156502e4c, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=黑色素性神经鞘瘤2例报道, objectType=article, longId=198388, objectId=d206198388fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d206198388fd, replyNumber=0, likeNumber=70, createdTime=2020-08-01, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d206198388fd, moduleTitle=黑色素性神经鞘瘤2例报道, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d206198388fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1565026, encodeId=525f156502651, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=NEJM：粘膜和手指黑色素瘤转移-病例报道, objectType=article, longId=197278, objectId=aa2e19e27840, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa2e19e27840, replyNumber=0, likeNumber=63, createdTime=2020-07-11, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa2e19e27840, moduleTitle=NEJM：粘膜和手指黑色素瘤转移-病例报道, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa2e19e27840)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1559017, encodeId=71b4155901e53, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=NEJM：粘膜和手指黑色素瘤转移-病例报道, objectType=article, longId=197278, objectId=aa2e19e27840, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa2e19e27840, replyNumber=0, likeNumber=60, createdTime=2020-07-11, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa2e19e27840, moduleTitle=NEJM：粘膜和手指黑色素瘤转移-病例报道, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa2e19e27840)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1565025, encodeId=b90015650258d, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=黑色素瘤癌症疫苗Seviprotimut-L，获得FDA快速通道认证, objectType=article, longId=196490, objectId=42171964903c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=42171964903c, replyNumber=0, likeNumber=75, createdTime=2020-06-27, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=42171964903c, moduleTitle=黑色素瘤癌症疫苗Seviprotimut-L，获得FDA快速通道认证, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=42171964903c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1559016, encodeId=c95d15590163a, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, objectTitle=黑色素瘤癌症疫苗Seviprotimut-L，获得FDA快速通道认证, objectType=article, longId=196490, objectId=42171964903c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=42171964903c, replyNumber=0, likeNumber=79, createdTime=2020-06-27, rootId=0, userName=cqlidoudou, userId=150614999302, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=42171964903c, moduleTitle=黑色素瘤癌症疫苗Seviprotimut-L，获得FDA快速通道认证, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=42171964903c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

黑色素

2020-05-29

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

PD1+溶瘤病毒，奥源和力公布OrienX010一项黑色素瘤Ib期研究结果

2020-09-23

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

PD1+溶瘤病毒，奥源和力公布OrienX010一项黑色素瘤Ib期研究结果

2020-09-23

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

Clin Cancer Res：抗疟疾药氯喹可增加GNAQ/11突变性黑色素瘤对MEK1/2抑制剂的敏感性！

2020-09-18

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

Clin Cancer Res：抗疟疾药氯喹可增加GNAQ/11突变性黑色素瘤对MEK1/2抑制剂的敏感性！

2020-09-18

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

NEJM：Dabrafenib联合Trametinib 治疗III期黑色素瘤患者长期生存数据喜人

2020-09-05

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

NEJM：Dabrafenib联合Trametinib 治疗III期黑色素瘤患者长期生存数据喜人

2020-09-05

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

Clin Cancer Res：靶向细胞外基质重构可恢复BRAFi耐药性黑色素瘤对BRAF抑制剂的敏感性

2020-08-30

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

Clin Cancer Res：靶向细胞外基质重构可恢复BRAFi耐药性黑色素瘤对BRAF抑制剂的敏感性

2020-08-30

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

Ann Oncol：黑色素瘤新辅助治疗后pCR患者的组织病理学特征与无复发生存相关

2020-08-09

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

Ann Oncol：黑色素瘤新辅助治疗后pCR患者的组织病理学特征与无复发生存相关

2020-08-09

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

肺原发黑色素瘤一例

2020-08-09

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

肺原发黑色素瘤一例

2020-08-09

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

罗氏PD-L1单抗Tecentriq联合靶向疗法：获FDA批准治疗晚期黑色素瘤

2020-08-03

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

罗氏PD-L1单抗Tecentriq联合靶向疗法：获FDA批准治疗晚期黑色素瘤

2020-08-03

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

黑色素性神经鞘瘤2例报道

2020-08-01

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

黑色素性神经鞘瘤2例报道

2020-08-01

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

NEJM：粘膜和手指黑色素瘤转移-病例报道

2020-07-11

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

NEJM：粘膜和手指黑色素瘤转移-病例报道

2020-07-11

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

黑色素瘤癌症疫苗Seviprotimut-L，获得FDA快速通道认证

2020-06-27

cqlidoudou (审核中...)

前往app查看评论内容

#黑色素#

黑色素瘤癌症疫苗Seviprotimut-L，获得FDA快速通道认证

2020-06-27

科室
- - 订阅+
  - 更多科室
工具
服务